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Cystinuria is an inherited disease that results in the formation of cystine stones in 
the kidney, which can have serious health complications. Two genes (SLC7A9 
and SLC3A1) that form an amino acid transporter are known to be responsible 
for the disease. Variants that cause the disease disrupt amino acid transport 
across the cell membrane, leading to the build-up of relatively insoluble cystine, 
resulting in formation of stones. Assessing the effects of each mutation is critical 
in order to provide tailored treatment options for patients. We used various 
computational methods to assess the effects of cystinuria associated mutations, 
utilising information on protein function, evolutionary conservation and natural 
population variation of the two genes. We also analysed the ability of some 
methods to predict the phenotypes of individuals with cystinuria, based on their 
genotypes, and compared this to clinical data. 
Results 
Using a literature search, we collated a set of 94 SLC3A1 and 58 SLC7A9 point 
mutations known to be associated with cystinuria. There are differences in 
sequence location, evolutionary conservation, allele frequency, and predicted 
effect on protein function between these mutations and other genetic variants of 
the same genes that occur in a large population. Structural analysis considered 
how these mutations might lead to cystinuria. For SLC7A9, many mutations swap 
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hydrophobic amino acids for charged amino acids or vice versa, while others 
affect known functional sites. For SLC3A1, functional information is currently 
insufficient to make confident predictions but mutations often result in the loss of 
hydrogen bonds and largely appear to affect protein stability. Finally, we showed 
that computational predictions of mutation severity were significantly correlated 
with the disease phenotypes of patients from a clinical study, despite different 
methods disagreeing for some of their predictions.   
Conclusions 
The results of this study are promising and highlight the areas of research which 
must now be pursued to better understand how mutations in SLC3A1 and 
SLC7A9 cause cystinuria. The application of our approach to a larger data set is 
essential, but we have shown that computational methods could play an 
important role in designing more effective personalised treatment options for 
patients with cystinuria.  
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Background 
Cystinuria is an inherited disorder resulting in urinary dibasic aminoaciduria [1]. 
The clinical presentation is varied; ranging from some patients having stone 
episodes every few months to other patients having only one stone in their 
lifetime. It is primarily caused by mutations in two genes; SLC3A1 encodes the 
neutral and basic amino acid transport protein (rBAT) and SLC7A9 encodes the 
light chain b amino acid transporter b(0+)AT [2] [3]. These two proteins form a 
dimer linked by a disulphide bridge [4]. b(0+)AT contains 12 transmembrane 
helices that form the channel through which dibasic amino acids (cystine, lysine, 
arginine and ornithine) are transported into the cell with the exchange of neutral 
amino acids. rBAT has a single transmembrane domain and a large extracellular 
domain. There is evidence to suggest that the extracellular glycosidase domain 
has a role in cystine transport but not the other dibasic amino acids [5]. rBAT also 
requires chaperones to fold correctly and some mutations have been linked with 
incorrect folding of the protein and/or trafficking to the plasma membrane [6].  
 
Experimental studies suggest that rBAT may function as an activator of b(0+)AT 
[3,7] but the functional role of rBAT remains unclear, although it is required for 
efficient transport to occur. Mutations in either of these two genes can result in 
defective transport of dibasic amino acids across the renal tubular membrane 
and intestine [8,9]. In the kidneys, this results in cystine accumulating in the urine 
and forming stones.  
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SLC3A1 mutations are inherited in an autosomal recessive pattern whilst 
mutations in SLC7A9 can be regarded as inherited in an autosomal dominant 
pattern with incomplete penetrance [10]. In SLC3A1, mutations in both alleles of 
the gene are required for disease presentation. In SLC7A9, some patients only 
have one mutation in one allele and can form cystine stones [11].  
 
Many mutations have been identified in both SLC3A1 and SLC7A9 in individuals 
with cystinuria [12] [13]. Frame shift, deletion, duplication, splice site and 
nonsense mutations typically result in large effects on the encoded protein and 
therefore its protein structure or function. Most mutations described in Cystinuria 
however, are missense mutations resulting in the change of a single amino acid 
in the protein. The effect of a missense mutation can range from having no effect 
on protein function to rendering it non-function. For many of the missense 
mutations in SLC3A1 or SLC7A9, without further analysis it is not clear what 
effect they have on protein function and how they lead to disease presentation.  
 
The sequencing of many people has demonstrated that each individual has 
between 4-5 million genetic variants compared to the reference human genome 
[14]. Some of these variants will cause disease or increase the risk of disease, 
however it is difficult from this large set of variants to identify those that are most 
likely to have a phenotypic effect and may have a role in disease. As a result 
many computational methods have been developed to predict if a genetic variant 
is likely to be deleterious (reviewed in [15]). These methods largely focus on the 
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analysis of non-synonymous single nucleotide variants (nsSNVs) and use many 
different features from sequence conservation to structural and functional 
information. Methods include SIFT [16,17], PolyPhen2 [18], SuSPect [19], 
VarMod [20], SNAP [21],  Mutation Assesor [22], FATHMM [23], CADD [24] and 
Condel [25]. 
 
We recently proposed that protein structural modelling and analysis of mutations 
present in cystinuria could be used to further our understanding of how mutations 
alter the function of the transporter and the extent of functional effect caused by 
each mutation [26]. Here we perform an extensive literature survey of clinical 
studies to identify the range of different mutations associated with cystinuria. A 
structural analysis of all the identified single point mutations present in rBAT and 
b(0+)AT is performed to investigate the effect of the mutations on the transporter 
structure and function. We also compare these mutations that have been 
reported to cause cystinuria with the natural variation of SLC3A1 and SLC7A9 
present in the large population study of genetic variation ExAC [27]. Finally, the 
ability of automated predictors to assess the effect of cystinuria associated 





Cystinuria literature survey 
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A literature search was performed to identify all clinical studies of cystinuria 
SDWLHQWV3XE0HGZDVVHDUFKHGZLWKWKHWHUPV³F\VWLQXULD´ ³F\VWLQXULDPXWDWLRQ´
DQG ³6/&$´ DQG ³6/&$´ Papers were first filtered on the basis of being 
original articles or reviews, with reviews discarded. Further filtering was 
performed by reading the abstracts of all papers to check for relevance. Those 




Genetic variation data was downloaded from the Exome Aggregation Consortium 
(ExAC) browser, for both SLC3A1 and SLC7A9, on 28/10/2016 [27]. This data 
set was then filtered to contain only variants that affect canonical transcripts, and 
then further filtered to contain only non-synonymous single nucleotide variants 
(nsSNVs). This resulted in a set of 318 and 144 nsSNVs not known to be 
associated with cystinuria for SLC3A1 and SLC7A9, respectively. 
 
The ExAC data was used to determine the allele frequencies of the variants 
identified by the literature search to have a role in cystinuria. In addition, all 
variants present in ExAC that were not identified to have a role in cystinuria form 
the SLC3A1 and SLC7A9 ExAC only variant sets.    
 
Structural modelling and analysis 
The protein structures of rBAT and b(0+)AT were modelled using the Phyre2 web 
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server [29]. Functional sites of the protein were modelled using multiple methods. 
The ligand binding sites including the amino acid, sugar and calcium binding 
sites were modelled using 3DLigandSite [30,31] and firestar [32]. Protein stability 
predictions were made using mCSM [33] for all nsSNVs. 
 
Residue conservation in rBAT and b(0+)AT was calculated using the following 
approach. Homologues were identified using BLAST [33] to search the 
UniProtKB with default parameters [34]. A multiple sequence alignment and a 
phylogenetic tree were generated for each of these sets of homologues using 
Clustal Omega with default parameters [35,36]. For each gene, the multiple 
sequence alignment, phylogenetic tree, and phyre2 structural model were 
submitted to ConSurf [37], which was run using the Bayesian prediction method 
with all other parameters set to default. The proteins used for the alignment, and 
the species that they come from, are shown in Supplementary Tables 1 and 2. 
For the 2 proteins, there were 158 common species, 87 species unique to the 
alignment of rBAT, and 45 species unique to the b(0+)AT alignment. This shows 
that the majority of the species used in the two alignments are the same, and 
there is not a large difference in the species distributions of the two alignments. 
This means that reasonable comparisons of conservation between the two 
proteins can be made.  
 
Clinical Data 
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Phenotypic data associated with cystinuria was available for a cohort of 74 
patients in the UK [28], consisting of 41 patients with mutations in SLC3A1, 32 in 
SLC7A9 and one patient without a mutation in either SLC3A1 or SLC7A9. 
Available phenotypic data included, urinary dibasic amino acids levels for 
cysteine, ornithine, arginine and lysine, the age of disease presentation, and the 
number of stone episodes and number of interventions over a three-year period. 
Two of the patients in this cohort were removed from this study as they had 
mutations in both SLC3A1 and SLC7A9. 
 
Automated prediction of the effect of mutations 
The mutations found in the literature search were submitted to SIFT [17], 
PolyPhen2 [18](using both predictive models HumDiv and HumVar), 
MutationAssessor [22], FATHMM [23], Condel [25] and CADD [24] using default 
settings. Condel and CADD differ from the other prediction methods in that they 
integrate predictions from individual methods to create an overall prediction. For 
example, Condel uses predictions from PolyPhen2, SIFT, Mutation Assessor, 
and FATHMM to make predictions. 
 
The different methods make predictions in different categories, SIFT only 
SUHGLFWV WZR FDWHJRULHV ³7ROHUDWHG´ DQG ³'DPDJLQJ´ DV GR )$7+00 &$''
and Condel QHXWUDO´DQG ³GDPDJLQJ´ZKLOH3RO\3KHQFDWHJRULVHVPXWDWLRQV
LQWRWKUHHFDWHJRULHV³EHQLJQ´³SRVVLEO\GDPDJLQJ´DQG³SUREDEO\GDPDJLQJ´DQG
0XWDWLRQ$VVHVVRU SUHGLFWV IRXU FDWHJRULHV ³QHXWUDO´ ³ORZ´ ³PHGLXP´ DQG
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 
 
PolyPhen-2 is available using two different training models, HumDiv and 
HumVar. These two models agree for 47 of 58 mutations in b(0+)AT and 81 of 94 
mutations in rBAT. As we want to distinguish between mildly deleterious and 
more severe mutations, the remaining analyses consider only the results using 
the HumVar training model. However, as shown above the two models give 
similar results. 
 
Grouping Patients by Mutation Severity and Comparison of Phenotypes 
The different categories of the prediction methods make analysis of the overlap 
of agreement between the methods difficult to assess. Therefore, the prediction 
scores made by each of the automated methods were classified into two groups, 
either mild or severe and these two groups were then associated with a score 
mild=1 and severe=2. Multiple thresholds for grouping mutations were tested for 
each of the prediction methods (see Supplementary Tables S3 and S4), starting 
from the recommended threshold for separating deleterious and neutral 
mutations for the specific method (see Table 1). The stringency of the threshold 
was then increased incrementally to separate the high confidence predictions 
from the medium confidence predictions. Thresholding above the cut-offs for 
deleterious vs neutral variants was necessary because these methods are 
designed to predict even mildly deleterious variants as deleterious, and we want 
to separate mild from severe mutations.  
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Frameshift, deletion, splice site and nonsense mutations are typically likely to 
have a significant effect on protein function and were therefore all assigned 
scores of 2. This may represent a simple scoring scheme but given the different 
categories and scoring scales of the different methods it appeared to be the most 
appropriate. 
 
Using the mutation scores from the predictive methods, each patient was 
assigned an overall severity score for the mutations that they have. As SLC7A9 
mutations show dominant inheritance with incomplete penetrance, for patients 
with SLC7A9 mutations, patient scores were the total of the scores for the 
individual mutations in each allele. This results in scores ranging from one (only 
one mild mutation present) to four (patient has two mutations classified as 
severe, one in each allele). 
 
A similar approach was taken for SLC3A1, but inheritance of cystinuria from 
SLC3A1 mutations is autosomal recessive, therefore mutations are required in 
both alleles to have the disease. For each patient, it was considered that the 
allele with the worst mutation would not be expressed while the other allele would 
be. For example, an individual with two mutations scored at 1, would have an 
overall score of 1, as would a patient with one mutation scored at 1 and the other 
at 2. Finally, an individual with two severe mutations would score 2 overall. This 
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strategy is valid for our dataset, because no individual has more than one 
mutation in a single allele of SLC3A1. 
 
The properties of each set of data were compared using the Wilcoxon rank sum 
test to find any statistically significant differences between the groups. All p-
values were corrected for multiple testing using the Bonferroni method.  
 
Statistical figures were produced using the R statistical package, version 3.2.1 
[38]. Additionally, plots with axes gaps were produced using the R package 
µSORWUL[¶[39]. 
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Results 
A literature search identified 52 articles, consisting of 49 original articles and 
three reviews. All of the original articles were deemed relevant from the abstract 
and read in full to extract data. From the clinical studies we identified a total of 94 
SLC3A1 and 58 SLC7A9 cystinuria associated point mutations. 
 
The 94 unique nsSNVs in SLC3A1 affect 81 different amino acid positions as 10 
residues have two variant amino acids and residue p.Arg365 has four different 
variant amino acids present. For SLC7A9 the 58 nsSNVs affect 55 different 
amino acid positions with only residues 105, 195 and 333 having two different 
variant amino acids.  
 
Initial Comparison of Cystinuria associated mutations with variation 
present in a large population. 
The ExAC resource [27] provides access to the variant frequencies from over 
60,000 individuals. We identified all variants present in SLC7A9 and SLC3A1 
(Supplementary Tables 5 and 6) to investigate the variation present in a large 
population of individuals and compare variants/mutations associated with 
cystinuria and those not associated with the disease. Worldwide prevalence of 
cystinuria is estimated at 1 in 7,000 [40], though variation by geographical 
location is large (1 in 100,000 in Sweden [41], and 1 in 2,500 in Libyan Jews [42]. 
Using the wordlwide prevalence, in the ExAC set of just over 60,000 individuals, 
we would therefore expect approximately nine individuals to have the disease.  
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The vast majority of cystinuria associated variants in both SLC7A9 and SLC3A1 
occur very rarely with an allele frequency of less than 0.01% and many are not 
present in the ExAC dataset (allele frequency of 0% - Figure 1C). This suggests 
that these variants are under purifying selection and that these mutations are 
deleterious. A few disease-associated variants have much higher frequencies 
(between 0.27%-31%). The cystinuria associated variant p.Val142Ala in SLC7A9 
has an allele frequency of 31% indicating that it regularly occurs in individuals. 
Given the high frequency of this variant it is likely that it has a limited effect on 
SLC7A9 function as cystinuria is a rare disease, this is reinforced by the low 
evolutionary conservation of residue 142 in the protein (ConSurf score of 1).  
 
Many non-disease associated variants in SLC7A9 and SLC3A1 also have low 
frequency (<0.01%; Figure 1C). For SLC7A9 there are a few variants with higher 
frequencies, and a considerable number more for SLC3A1. This demonstrates 
that there is limited variation in SLC3A1 and SLC7A9 in the population. The 
higher frequency of variants in SLC3A1 may reflect that it has autosomal 
recessive inheritance, whereas SLC7A9 inheritance is autosomal dominant with 
incomplete penetrance. Thus, a single SLC7A9 allele can result in cystinuria. 
 
At the protein level there appears to be some clustering of the rBAT cystinuria 
associated point mutations in sequence (Figure 1B). For example, there are 
some mutated positions that occur in stretches throughout the protein (including 
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121-124, 253-256, 480-482, 552-568). While some ExAC variation occurs in the 
same sequence regions, there appears to be less clustering of these variants 
and ExAC only variants largely occur in parts of the protein sequence where 
cystinuria associated mutations are not present (Figure 1B). 
 
For b(0+)AT, unlike rBAT, there is less evidence of clustering of the amino acids 
that are mutated, with no runs of residues being mutated and only a few 
examples of adjacent residues being mutated (Figure 1A). Again, there is limited 
overlap with ExAC variation data (Figure 1A). 
 
The conservation of each variant position was calculated using ConSurf (see 
Methods). The conservation scores range from 1-9, with 1 being the most 
variable and 9 the most conserved. For both genes, there is a clear difference in 
the distributions between the mutations known to be associated with cystinuria 
and the variants only found in ExAC (p=1.69e-10 for SLC3A1, and p= 2.078e-06 
for SLC7A9, Wilcoxon rank sum test) (Figure 2). The cystinuria associated 
mutations of both genes are predominantly at positions with high ConSurf scores, 
suggesting that these positions are of high importance to the function of the 
protein. This skew is larger for SLC7A9, where ~80% of the mutations have 
ConSurf scores between 6 and 9 (Figures 1A-B and 2A-B). Conversely, for both 
genes, a large number of variants that are not known to be associated with 
cystinuria have ConSurf scores of 1 (Figures 1A-B and 2C-D), suggesting that 
the functional roles of these positions are minimal. This agrees with these 
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variants being neutral, as such positions are less likely to have an effect on 
protein structure or function. Around 40% of the positions of ExAC only variants 
have ConSurf scores between 6 and 9, it is possible that they may have some 
effect upon protein function or that the variants observed conserve the property 
of the wild type amino acid more so than the cystinuria associated mutations. We 
did not observe a correlation between ExAC allele frequency and ConSurf 




Protein structural modelling 
To investigate where in the protein structure the cystinuria associated variants 
occur and to analyse the effect they may have on protein structure and function, 
protein structural modelling of the protein was performed. Phyre2 [29] generated 
high confidence structural models of both b(0+)AT and rBAT (Figure 3). For 
rBAT, the extracellular alpha amaylase-like domain was modelled using the 
structure of Bacillus Cereus oligo-1,6-glucosidase [43] as a template (pdb code: 
1uok). The structure of a glutamate and Ȗ-aminobutyric acid antiporter [44] (pdb 
code: 4DJI ) was used as the template structure for modelling b(0+)AT.  
 
The b(0+)AT protein transports dibasic amino acids into the cell in exchange for 
neutral amino acids. There are therefore two sites for amino acid binding, one on 
each side of the transporter. The outward facing binding site was modelled using 
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3DLigandSite and firestar using the Arginine bound to another related APC 
transport (AdiC, pdb code: 3OBM) [43]. To model the inward facing conformation, 
the putative binding site identified for ApcT (another member of the APC 
transporter family) was mapped onto our model [45] (Figure 3A). 
 
Studies have proposed that Lys158 in ApcT has a role equivalent to sodium in 
sodium dependent transporters [46]. This lysine is conserved in b(0+)AT 
(Lys184) and three of the four residues coordinating with it are also conserved 
(Gly41, Ile44, Ser312). 
 
Overall potential functional residues identified in b(0+)AT for amino acid binding 
were: Ile38, Thr42, Ile43, Ser46, Gly47, Val50, Thr91, Lys92, Leu117, Lys121, 
Ser124, Ile128, Trp230, Ala231, Tyr232, Ile371. As the mechanism of transport is 
not clearly understood there are likely to be further residues that are functionally 
important that have not been identified here.  
 
In rBAT the residues predicted to have a potential functional role in the alpha 
amylase domain for sugar binding were: Asp172, Tyr175, His215, Val258, 
Tyr259, Phe278, Met279, Gln282, Ser312, Asp314, Ala315, Phe318, Glu384, 
Asp449 (Figure 3B). Additionally, Asp133, Asn135, Asp137, Asn139, Asp141 are 
predicted to bind calcium (Figure 3B). However, it is not clear if rBAT binds sugar 
molecules or if it has an alpha amylase enzyme activity. 
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Structural analysis of mutations in b(0+)AT  
Initial analysis of the substitutions that occur in b(0+)AT shows that for only 22 of 
the 58 point mutations the type of amino acid is not changed (Table 2). The 
majority of residues that are mutated are hydrophobic and for more than half of 
the changes (25 of 45) the mutated residue is polar or charged. This shows that 
mutations are regularly introducing charge into the protein. 
 
The likely effects of the mutations fall into a few categories (full analysis details in 
Supplementary Table S7). Firstly, some mutations alter residues with a functional 
role (e.g. ligand binding) or they are located close to functional sites. Secondly, 
some mutations seem likely to alter protein conformation as they either introduce 
charge or change the size/shape of the sidechain (often in buried or densely 
packed regions of the protein). Finally, some mutations are located on the protein 
surface and they could affect the interaction with the membrane or with rBAT. 
 
There are a set of mutations close to the functional residue Lys184, which is 
likely to function in an equivalent way to sodium in sodium dependent 
transporters. One of the residues thought to coordinate with Lys184, Ile44, is 
mutated to Thr (Figure 4A). Additionally, in the same area there are the 
mutations p.Ile36Asn, p.Val40Met, p.Ala182Thr, p.Ile187Phe, p.Val188Met and 
p.Pro261Leu (Figure 4A). Many of these mutations seem fairly conservative, and 
suggest that minor changes to the conformation of the protein, through altered 
packing of sidechains may be sufficient to alter function. This may be particularly 
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relevant as helix 1 (containing p.Ile36Asn, p.Val40Met, p.Ile44Thr) is thought to 
undergo conformational change during transport and the other side of the helix 
contains multiple residues that are likely to have a role in binding the transported 
amino acids (Figure 4A ± cyan coloured residues).  
 
Other mutations are close to the residues likely to have a functional role in 
transporting the amino acids. One of these functional residues, Trp230, is 
mutated to Arg (Figure 4B) and there are multiple other mutations in the same 
area that are close to functional residues (Figure 4B-D).  
 
b(0+)AT contains many hydrophobic amino acids, which are often tightly packed. 
In multiple examples, a smaller hydrophobic is replaced by either a polar/charged 
amino acid or a larger hydrophobic (for example p.Gly319Arg - Figure 4C). 
 
A final group of mutations may affect the interactions of the protein with the lipid 
bilayer and its stability. Most of these mutations either introduce (p. Tyr99His, 
p.Ala109Thr, p.Cys137Arg, p.Phe140Ser, p.Gly195Arg, p.Tyr457His), remove 
(p.Arg171Trp, p.Asp333Trp) or alter charge (p.Arg250Lys, p.lys401Arg) mainly at 
the end of helices on the protein surface near the end of the membrane 
(examples shown in Figure 4D). Another possible impact of mutations on the 
protein surface of b(0+)AT (and also rBAT) is that they interfere with the 
dimerization of the two proteins. However, little is known about how these two 
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proteins interact and what residues are involved in the interaction, so predictions 
of the impact on dimerization were not possible. 
 
Structural analysis of mutations in rBAT 
While rBAT has an alpha-amylase like extracellular domain, the functional role of 
this domain has not been well established. Overall there are few mutations 
present (only three) in or near the predicted functional residues (based on 
possible sugar and calcium binding sites) (Figure 3B). This suggests that these 
residues may not be functional in rBAT, otherwise mutations would be expected 
to occur here as was seen for mutations in b(0+)AT (although ConSurf shows 
that these residues are highly conserved, 11 of the 14 have scores of 8 or 9). It 
suggests that we do not know what residues are functionally important in rBAT 
and what function they perform. This makes the structural analysis difficult. 
 
Despite this D IHZ PXWDWLRQV DUH ORFDWHG FORVH WR ³IXQFWLRQDO´ UHJLRQV RI WKH
protein. p.Arg137Gly is one of the residues predicted to bind Calcium, mutation 
to glycine would lose the positive charge in this region. Similarly, p.Gly140Arg is 
present within the loop where calcium is modelled to be bound (Figure 4E). This 
position is completely invariant in homologues (with a maximum ConSurf score of 
9) suggesting an important structural/functional role for this residue. Introduction 
of a positively charged arginine may be expected to interfere with the binding of 
the positively charged calcium ion (assuming that Calcium does bind here). 
p.Thr189Met is located in the alpha helix adjacent to the calcium binding site so it 
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is possible that destabilisation here could affect the calcium binding site (Figure 
4E). Three of the mutations (p.Met381Thr, p.Tyr397Cys, p.Gly398Arg) are close 
to what would be the active site if the protein was an active hydrolase. p.Met381 
is highly conserved in orthologues and the mutation to threonine could introduce 
a polar contact with p.Asp369. Similarly p.Gly398Arg would introduce a charge 
and a larger sidechain. For p.Tyr397Cys the mutation is likely to remove a 
hydrogen bond (see below).  
 
Overall the structural analysis suggests that, for the majority of the rBAT 
mutations observed, they may have an effect on the structure or stability of the 
protein (full structural analysis details in supplementary Table 8). These 
mutations fall into two main groups. In the first group, a hydrophobic amino acid 
is replaced by a polar or charged amino acid (examples are p.Tyr151Cys, 
p.Leu205Ser, p.Leu300Ser, p.Tyr397Cys, p.Tyr461His, p.Met467Thr, 
p.Ile445Thr, p.Tyr579Asp, p.Phe599Ser) where the hydrophobic side chain is 
typically buried and packed against other hydrophobic side chains. Of the 49 
hydrophobic sidechains that are mutated, 17 are changed to charged amino 
acids and 15 to polar sidechains (Table 3). In the second group, a polar or 
charged amino acid is typically replaced by a hydrophobic side chain (but in 
some cases a different polar/charged sidechain) and modelling suggests that 
these mutations often remove hydrogen bonds or salt bridges that stabilise the 
protein structure (Figure 4F-I). Of the 45 polar or charged residues that are 
mutated, 33 are likely to result in loss of hydrogen bonding (Supplementary Table 
Page 22 of 53 
8) and half of them (23) are changed to hydrophobic amino acids (Table 3). 
Examples of these mutations include p.Thr189Met, p.Thr216Met, p.Thr341Ala, 
p.Arg365Leu, p.Arg452Trp, p.Ser455Leu, p.Ser547Leu (examples shown in 
Figure 4F-I; supplementary Table 8). 
 
The remaining mutations either change the polarity or charge of the sidechain 
(Table 3) or result in a considerable change in the size of the sidechain. Of the 
94 mutations only 21 remain in the same group (i.e. hydrophobic, polar, positive 
or negative charge; Table 3). For the 17 mutations that replace a hydrophobic 
amino acid with another hydrophobic sidechain, five see a considerable increase 
in sidechain size (e.g., p.Leu256Phe, p.Gly645Ala) and for a further six the size 
of the sidechain is reduced (e.g. p.Tyr124Cys, p.Trp255Cys (Figure 4I), 
p.Tyr480Cys).  
 
The initial sequence analysis suggested clustering of mutations (Figure 1). This 
was also apparent from the structural analysis. There are multiple examples of 
mutated residues that are close in three dimensions that are not adjacent in 
sequence. These include: p.Tyr124-p.Tyr151-p.Tyr480, which appear to have Pi 
interactions between their aromatic sidechains; p.Trp161-p.Asp210, p.Asp179-
p.Arg181, p.Arg452-p.Tyr480, p.Arg584-p.Thr417 and p.Tye552His-p.Glu482Lys 
each of which form a hydrogen bond between them (e.g. Figure 4G); and 
p.Phe22-p.Glu268-p.Arg270-p.Arg227 and a large group including residues 
p.Met467-p.Thr471-p.Leu564-p.Leu567-p.Gly568-p.Tyr582. This clustering 
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suggests that these are regions that either have important structural or functional 
roles, where mutation of any of them results in changes to protein function. 
 
Given the presence of multiple variants that appear to affect protein stability, 
mCSM [32] was used to predict the effects of nsSNVs on protein stability. For 
mCSM, negative ''G values are destabilising for a protein structure, and 
positive ''G values are stabilising (Figure 2E-H). rBAT variants known to be 
associated with cystinuria appear to be distributed more towards negative ''G 
values than variants present only in ExAC, with median values of -1.122 and -
0.668 respectively (p=7.896e-06, Wilcoxon rank sum test) (Figure 2E&F). 
Compared to cystinuria associated nsSNVs in b(0+)AT, a greater proportion in 
rBAT are predicted to be highly destabilizing to the protein (median rBAT value of 
-1.122, and -0.889 for b(0+)AT) (Figure 2E&G), supporting the observation that 
rBAT variants are more likely to destabilize the protein structure. However, this 
just falls short of statistical significance (p=0.05068, Wilcoxon rank sum test).  
 
Automated prediction of effects of mutations in rBAT and b(0+)AT 
There are many automated methods available to predict the effect of non-
synonymous SNVs. Six of these methods, SIFT, PolyPhen-2, MutationAssessor, 
FATHMM, Condel, and CADD (note Condel and CADD are consensus methods 
that combine the output from multiple individual predicton methods to generate 
an overall prediction) were used to predict the effect of each of the mutations 
present in rBAT and b(0+)AT (see methods). This was done to compare the 
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predictions made with clinical data from a cohort of 74 patients in a UK cystinuria 
clinic [28]. The predictions made by each of the methods are summarised in 
Table 4 (full predictions in Supplementary Tables 9 and 10).  
 
For 20 b(0+)AT (of 58) and 31 (of 94) rBAT mutations all methods make the most 
deleterious predictions. No mutations in either protein were predicted by all six 
methods to have the lowest or mildest effect on function. For both proteins, the 
methods agree for a similar proportion of mutations (32.9% for b(0+)AT, 34.5% 
for rBAT).   
 
The effects of three mutations in b(0+)AT (p.Gly105Arg, p.Ala182Thr  and 
p.Arg333Trp) have been experimentally characterised. We compared the 
predictions with the known effects (Table 5) and observed good agreement. For 
b(0+)AT two (p.Gly105Arg and p.Arg333Trp) of the three characterised mutations 
reduce amino acid transport to 10% of wild type and for both of these mutations 
all methods predict the greatest effect (Table 5). The third mutation (p.Ala182Thr) 
reduces transport to 60% of wild type and three methods predict that this 
mutation will have a limited or no effect on the protein, and three predict that it 
will be damaging.  
 
Comparison of functional effect predictions with patient phenotype 
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We considered how well the predicted effects of the mutations agreed with the 
observed phenotypes of patients, based on the grouping of the patients by the 
prediction scores (see methods). Each mutation was assigned a severity score of 
either 1 (mild) or 2 (severe) based on the prediction score from the predictive 
method. Then for each individual an overall severity score was calculated based 
on the mutations present (see methods). The patients were grouped according to 
their overall score and the phenotype data compared between the different 
groups (see methods). 
 
As the predictive methods associate a score (or probability) with their predictions 
we first investigated how altering the threshold between assigning a mutation to 
the mild or severe group affected the outcome of the comparisons. For each 
mutation effect prediction method, the number of patients in each severity score 
group stabilised over a range of prediction score thresholds, e.g. for PolyPhen2 
the groupings are stable between thresholds of шϬ͘ϲϱ and шϬ͘ϴϬ͘ A single 
threshold within these ranges was then chosen as the cutoff between mild and 
severe mutations for that method and used for comparison (Table 1 and 
Supplementary Tables S3 and S4). 
 
First b(0+)AT was considered, (Figures 5, 6A, S2, and S3). Each of the prediction 
methods sorted the patients in to slightly different groupings, but various general 
trends were observed across the methods. Considering the urinary levels of the 
amino acids arginine, ornithine, lysine and cystine, for all methods there was a 
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general trend for the levels to be higher in the high severity score groups. For 
each method the difference seems greatest for arginine, and for SIFT and CADD 
there was a significant difference between severity score groups 3 and 4 for the 
levels of arginine (Figures 5 and 6A).  
 
The age of diagnosis and the number of stone episodes and interventions over a 
three-year period were also considered. Again, the average values for the higher 
severity score groups typically followed the pattern that may be expected i.e. 
lower severity score group have a later age of presentation and lower number of 
stone episodes and interventions (Figures S2 & S3). Many of these values have 
large ranges (as demonstrated by the error bars), but some of these 
comparisons showed statistical significance, e.g. PolyPhen2 predicted groups 3 
and 4 show a significant difference for the number of interventions (p=0.017) and 
age of diagnosis for Mutation Assessor and Condel predicted groups 3 and 4 
(p=0.015 and p=0.014, respectively).  
 
The equivalent analysis was performed for patients with mutations in rBAT. For 
rBAT there are only two categories ± mild (score 1) and severe (score 2) (details 
in methods). For all of the urinary amino acid levels and for all predictive methods 
the average for severity score group 1 was lower than for severity score group 2 
(Figures 6B & 7). These differences in arginine levels were statistically significant 
across all methods. The differences in ornithine and lysine levels were 
statistically significant for PolyPhen2, Mutation Assessor, and CADD, and the 
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difference in ornithine was significant for Condel. No method found a statistically 
significant difference between the groups for cystine levels. However, there are 
difficulties in the accurate measurement of cystine, so this result is unlikely to be 
reliable and the other levels of other amino acids are a better indicator of disease 
severity. 
 
Patients in severity score group 1 for all methods present with disease at a later 
age than those in severtity group 2, though these differences are not statistically 
significant (Figures S4 & S5). There is little difference between the average 
number of stone episodes for the two groups (for all predictive methods) and for 
SIFT the number of interventions is greater in the lower severity score group 
(Figure S4 & S5). 
 
All methods struggle to identify differences in the age of diagnosis, number of 
stone episodes and number of interventions, but they are better at finding 
differences in the urinary amino acid levels between the severity score groups. 
This is perhaps because urinary amino acid levels are a less complex phenotype, 
which was directly measured. In contrast the other phenotypes are less easily 
measured or recorded. For example, a patient may present with a large number 
of stones which all pass spontaneously, whereas another patient may present 
with fewer more serious stone episodes. The measurements taken may depend 
on patients accurately recording the number of stones that pass and medical 
interventions may also affect the number of stone episodes. Therefore, 
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We have surveyed the mutations present in SLC7A9 and SLC3A1 and their likely 
effect on the encoded proteins b(0+)AT and rBAT. Across 49 studies, 58 and 94 
cystinuria associated point mutations were identified in SLC7A9 and SLC3A1, 
respectively. Our initial comparison of cystinuria associated variants with variants 
present only in ExAC, showed that the disease associated variants typically have 
a lower frequency in the population, they tend to cluster in the protein sequence, 
largely in different areas of the protein sequence to the ExAC variants which 
show less clustering. This may suggest that particular regions of the protein 
sequence cannot be altered without affecting protein function. Additionally, we 
found that the frequency of ExAC variants was higher for SLC3A1, which may 
represent the autosomal recessive inheritance of cystinuria when caused by 
SLC3A1 mutations. 
 
Using structural models to investigate mutations in rBAT was more complicated 
than for b(0+)AT because the function of rBAT is not clearly understood. 
Interestingly in rBAT, few mutations directly affected the predicted functional 
residues that would be associated with the enzyme activity that is typically 
present in this family of proteins. However, a large number of mutations either 
remove hydrogen bonds or introduce a charge into a buried or hydrophobic 
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region and could therefore disrupt protein folding or reduce stability. This is 
consistent with what we know of the rBAT protein; experimental studies suggest 
that the heavy rBAT subunit is essential for cell surface expression of b(0+)AT 
and essential for transport of the heterodimer to the plasma membrane [3]. The 
extracellular glycosidase domain may only have a role in cystine transport [5] and 
the requirement of chaperone for rBAT to fold correctly. A number of rBAT 
mutations have been linked with incorrect folding of the protein and/or trafficking 
to the plasma membrane [6]. 
 
In contrast, it is known that the light chain b(0+)AT encoded by SLC7A9 forms 
the exchanger of dibasic amino acids for neutral amino acids [47]. In fact, it has 
been suggested that the light subunit may be fully functional even in the absence 
of the heavy subunit [8,9,48,49]. Given the important functional role of b(0+)AT in 
amino acid transport, multiple cystinuria associated mutations are identified that 
affect or are close to predicted functional residues. Additionally, other mutations 
either seem likely to result in conformational changes or affect protein stability. 
For example, there are many examples where a buried hydrophobic amino acid 
is replaced by a charged or polar one but in contrast to rBAT there are few 
mutations that remove hydrogen bonding, which is likely because b(0+)AT is 
highly hydrophobic. 
 
Comparison between the different variant effect predictors indicated that they 
agree for approximately 30-35% of point mutations. The investigation of using 
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these methods to classify patients¶ disease into mild and severe, has a number of 
limitations. The methods used have been developed to predict amino acid 
changes that are likely to cause disease and we see that they do this fairly well 
for the mutations considered, with most of them predicted to be deleterious. So, 
we have not used them here for exactly the role they were developed. The 
scoring system may be overly simple, a patient with two low severity mutations 
will perhaps fair better than an individual with one severe mutation (or vice 
versa), but they are treated equally in our scoring system. Additionally, the 
sample size is relatively small. Finally, the complex inheritance patterns of 
b(0+)AT makes predictions of mutation effect harder. For rBAT, the pattern is 
clearer with high severity score groups tending to worse phenotypes (see Figures 
6B, 7, S4, and S5). 
 
However, given these limitations the analysis suggests the potential for the use 
of such methods in this way. Typically, we observed the phenotype differences 
that would be expected, if those predicted in the lower severity score group 
actually had a milder form of the disease. For example, the urine levels of nearly 
all of the amino acids considered (for most of the methods) across both proteins, 
are lower for the lower severity score group (but not all are statistically 
significant). Additionally, for rBAT and b(0+)AT there are general trends for most 
methods where the age of presentation is higher in the low severity score groups, 
while the number of stone episodes and number of interventions is greater in the 
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high severity score groups, but this is mostly not statistically significant, which 
highlights the need to use a larger cohort. 
 
Overall these results are promising. Methods used to predict if mutations are 
deleterious have been used to categorise mutations and there is some 
correlation with phenotype. However, it also highlights the limitations of existing 
methods and improvements are required if they are to be used for even relatively 
simple precision medicine applications such as the classification of cystinuria 
disease severity. Additionally, the analyses performed here need to be expanded 
into a larger cohort of individuals to obtain greater confidence and to identify the 
most effective way to categorise individuals. With a larger dataset there would be 
the potential to train a method specifically to classify individuals based on their 
SLC3A1 or SLC7A9 mutations, which may be more effective than trying to use 
existing methods that have not been designed specifically to do this. Following 
this there is the potential to investigate the use of such an approach to provide 
individual precision treatment in the clinic. 
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Figure 1. Mutations present in b(0+)AT (SLC7A9) and rBAT (SLC3A1) in 
patients with cystinuria. Plots of the sequence of A) b(0+)AT and B) rBAT. For 
each protein the location of cystinuria associated mutations is shown (red circles) 
with the position of variants present in ExAC (blue circles). The conservation 
score is shown (grey line with values ranging from 1-9). The lower bar shows the 
protein secondary structure. C) Total population allele frequencies based on the 
ExAC data set. Each point represents an allele frequency. Multiple variants may 
have the same allele frequency, and the number of variants with the specific 
allele frequency is represented by the position of the point on the Y axis. The 
individual plots correspond to the four different sets of variants. C(A.) Variants of 
SLC3A1 reported to be associated with cystinuria. C(B.) Variants of SLC7A9 
reported to be associated with cystinuria. C(C.) Variants of SLC3A1 not reported 
to be associated with cystinuria but present in ExAC. C(D.) Variants of SLC7A9 
not reported to be associated with cystinuria but present in ExAC. 
    
Figure 2. Conservation of nsSNVs in SLC7A9 and SLC3A1 and their predicted 
effect on protein stability. A-D) Distribution of Consurf conservation scores for 
nsSNVs in SLC7A9 and SLC3A1 that are either i) present in individuals with 
cystinuria (A and B) or ii) present in the ExAC dataset (C and D). ConSurf scores 
vary between 1 and 9, with 9 being highly conserved and 1 being not conserved.  
E-H). Effect of nsSNV on protein stability predicted by mCSM. mCSM predicts 
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the change in Gibbs free energy (kcal/mol) negative values indicate 
destabilisation and positive values stabilisation. 
 
Figure 3. Structural models of rBAT and b(0+)AT. For both proteins cystinuria 
associated mutations are coloured red. A) Model of b(0+)AT. Residues modelled 
to contact the transported amino acids are coloured cyan. The conserved 
p.Lys184 and residue coordinating with it are coloured magenta. B) Model of 
rBAT. The modelled sugar binding site residues are coloured cyan and the 
predicted calcium binding site is magenta. 
 
Figure 4. Mutations in b(0+)AT and rBAT. In all images the mutated residues are 
displayed as red sticks in their wild type format. Predicted functional residues are 
coloured cyan. Hydrogen bonds are shown as dashed black lines. Images A-D 
refer to b(0+)AT and images E-I refer to rBAT. A). p.Ile187Phe and p.Ala182Thr 
mutations are adjacent to p.Lys184 which is thought to play a role equivalent to 
sodium in sodium dependent transporters. B) p.Trp230Arg (coloured blue) is 
adjacent to multiple functional residues C) The mutation p.Gly319Arg occurs in a 
buried region (p.Gly319 shown in red spheres) D). Mutations close to the end of 
transmembrane helices may reduce stability in the membrane. E) mutations 
occurring close to the predicted calcium binding site in rBAT. F) mutation 
p.Ser547Leu will remove hydrogen bonding. G) p.Tyr552His and p.Glu482Lys as 
wild type form a hydrogen bond, it is not clear if this will be retained upon 
mutation. H) multiple mutations present in a single region. p.Leu472Phe (orange 
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spheres) will result in increased size in well packed area. Other mutations will 
remove hydrogen bonding. I) Mutations occur in residues 253-256. 
 
 
Figure 5. Comparison of average urine levels of amino acids between the 
different severity score groups, for individuals with b(o+)AT mutations. There is 
one plot per prediction method (PolyPhen2, SIFT Mutation Assessor, and 
FATHMM). The group numbers are given at the bottom of the plots, with the 
sample number given in brackets underneath the group name. Where significant 
differences between groups occur (p<0.05) the p-value is displayed on the plot, 
e.g. (1-2)p=0.001 means a significant difference between groups 1 and 2. 
 
Figure 6. Comparison of average urine levels of amino acids between the 
different severity score groups using Condel and CADD. A) Individuals with 
b(o+)AT mutations. B) Individuals with rBAT mutations. There is one plot per 
integrated prediction method (CADD and Condel) for each gene. The group 
numbers are given at the bottom of the plots, with the sample number given in 
brackets underneath the group name. Where significant differences between 
groups occur (p<0.05) the p-value is displayed on the plot, e.g. (1-2)p=0.001 
means a significant difference between groups 1 and 2. 
 
Figure 7. Comparison of average urine levels of amino acids between the 
different severity score groups, for individuals with rBAT mutations. There is one 
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plot per prediction method (PolyPhen2, SIFT Mutation Assessor, and FATHMM). 
The group numbers are given at the bottom of the plots, with the sample number 
given in brackets underneath the group name. Where significant differences 
between groups occur (p<0.05) the p-value is displayed on the plot, e.g. (1-




Table 1. Mutation severity prediction score thresholds used for each method. 
Based on stabilisation of group numbers above the recommended deleterious 
threshold 
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Table 3. Type of amino acid change for mutations in rBAT  
Table 4 ± Summary of effects of mutations predicted by the automated methods. 
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Table 1. Mutation severity prediction score thresholds used for each method, 
based on stabilisation of group numbers above the recommended deleterious 
threshold 
 
Method Standard Deleterious 
Threshold 
Threshold for Mutation 
Severity Score of 1 
Threshold for Mutation 
Severity Score of 2 
SIFT Score < 0.05 Score > 0.025 6FRUH 
PolyPhen2 6FRUH Score < 0.80 6FRUH 
Mutation Assessor Score > 1.9 Score < 2.7 6FRUH 
FATHMM 6FRUH-1.5 6FRUH-8.5 Score < -8.5 
Condel Score > 0.522 Score  0.672 Score > 0.672 
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Table 2. Type of amino acid change for mutations in b(0+)AT 
 


















Hydrophobic Polar Positive Negative Total 
Hydrophobic 20 10 12 3 45 
Polar 5 0 1 1 7 
Positive 2 1 1 1 5 
Negative 0 0 0 1 1 
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Table 3. Type of amino acid change for mutations in rBAT 
 


















Hydrophobic Polar Positive Negative Total 
Hydrophobic 17 15 13 4 49 
Polar 10 2 6 2 20 
Positive 10 5 2 0 17 
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Table 4 ± Summary of effects of mutations predicted by the automated methods. 
 
 rBAT b(0+)AT 
SIFT ± Tolerated 23 11 
SIFT ± Damaging 70 48 
   
PolyPhen2 (HumVar) ± benign 12 14 
PolyPhen2 (HumVar)  ± possibly damaging 15 16 
PolyPhen2 (HumVar) ± probably damaging 66 29 
   
PolyPhen2 (HumDiv) ± benign 8 15 
PolyPhen2 (HumDiv)  ± possibly damaging 11 4 
PolyPhen2 (HumDiv) ± probably damaging 74 40 
   
MutationAssessor ± neutral 2 4 
MutationAssessor ± low 17 6 
MutationAssessor ± medium 40 29 
MutationAssessor - high 34 20 
FATHMM ± Neutral  0 0 
FATHMM ± Damaging 93 59 
Condel - Neutral 1 7 
Condel ± Damaging 92 52 
CADD- Neutral 5 6 
CADD - Deleterious 88 53 
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